

**SB 37 - AS INTRODUCED**

2021 SESSION

21-0882

06/04

SENATE BILL **37**

AN ACT relative to warning label requirements for marijuana products dispensed in alternative treatment centers.

SPONSORS: Sen. Gannon, Dist 23; Sen. D'Allesandro, Dist 20; Sen. Ward, Dist 8; Rep. M. Pearson, Rock. 34; Sen. Giuda, Dist 2; Sen. Prentiss, Dist 5; Rep. Weyler, Rock. 13

COMMITTEE: Commerce

---

ANALYSIS

This bill requires the department of health and human services to adopt rules that include certain specific information on marijuana product labels dispensed in alternative treatment centers.

-----

Explanation: Matter added to current law appears in ***bold italics***.  
Matter removed from current law appears ~~[in brackets and struckthrough]~~  
Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

## STATE OF NEW HAMPSHIRE

*In the Year of Our Lord Two Thousand Twenty One*

AN ACT                    relative to warning label requirements for marijuana products dispensed in alternative treatment centers.

*Be it Enacted by the Senate and House of Representatives in General Court convened:*

1            1 Findings. The general court recognizes that the side effects and risks of marijuana use on the  
2 human body have advanced to a point that requires the department of health and human services to  
3 update agency rules on packaging and labeling requirements for marijuana products dispensed in  
4 alternative treatment centers. No detailed side effects or risks of use exist on current warning  
5 labels.

6            2 Use of Cannabis for Therapeutic Purposes; Rules. Amend RSA 126-X:6, III(a)(9) to read as  
7 follows:

8                            (9) Labeling standards.

9                            ***(A) Labels shall include a statement that the product has not been***  
10 ***analyzed or approved by the FDA, is not certified to be free of contaminants, that there is***  
11 ***limited detailed information on the side effects of using the product, and that there may be***  
12 ***serious associated health risks.***

13                            ***(B) Labels shall also state "Do not drive or operate heavy machinery***  
14 ***when under the influence of this product. KEEP THIS PRODUCT AWAY FROM***  
15 ***CHILDREN"; and***

16                            ***(C) Labels shall include side effects and use risks published by Centers***  
17 ***for Disease Control and Prevention, National Institute on Drug Abuse, the National***  
18 ***Academy of Sciences and the American Academy of Family Physicians. They shall include***  
19 ***but not be limited to: psychosis and schizophrenia, depression, anxiety, suicide, increased***  
20 ***blood pressure, increased respiratory rates, cardiac arrhythmia, heart failure, worsening***  
21 ***of glaucoma, cognitive impairment, addiction, allergic reactions, accidental poisoning and***  
22 ***coma in children, preterm births to pregnant women, and impacts on fetal brain***  
23 ***development.***

24            3 New Paragraph; Use of Cannabis for Therapeutic Purposes; Duties. Amend RSA 132:2 by  
25 inserting after paragraph XI the following new paragraph:

26                    XII. Prepare, in conjunction with the bureau of alcohol and drug services and the division of  
27 public health services, a brochure and a poster which provides information relative to the known  
28 side effects and risks of marijuana use which shall be posted in a conspicuous location and available  
29 to the public in all therapeutic cannabis dispensary locations pursuant to RSA 126-X:8.

30            4 Effective Date. This act shall take effect 60 days after its passage.